"This alliance delivers us immediate speed and efficiency to our drug development efforts resulting in quality clinical trial data at high levels of regulatory compliance," stated Tom Davis, arGentis' Chief Executive Officer. "Target Health's proven track record of NDA and PMA approvals verifies that we will be able to accrue valuable clinical study performance through enhanced planning and achieve favorable end points to our trials."